Press releaseGlobe Newswire
Vera Therapeutics
VERA · NASDAQ
$30.06+$1.14 (+3.94%)TodayMarket closed ·
Prev close $28.92
Latest news
- NewsAvi Kapoor
Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Press releaseGlobe Newswire
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
- NewsVandana Singh
What's Going on With Vera Therapeutics Stock on Tuesday?
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
- Press releaseGlobe Newswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
- NewsAvi Kapoor
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseGlobe Newswire
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
- NewsAvi Kapoor
Kura Sushi Posts Weak Q3 Sales, Joins FuelCell Energy And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- NewsVandana Singh
Why Is Vera Therapeutics Stock Gaining Tuesday?
- Press releaseGlobe Newswire
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
- News
FDA Approves Vera Therapeutics' Trutakna For Treatment Of Proteinuria In Adults With Primary Immunoglobulin A Nephropathy
- NewsVandana Singh
What's Going on with Vera Therapeutics Stock on Monday?
- Press releaseGlobe Newswire
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
- NewsVandana Singh
FDA Fast-Tracks Vera's At-Home Kidney Drug
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Nutanix Posts Downbeat Q1 Results, Joins HP, Ambarella, Pagerduty And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
- NewsVandana Singh
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
- NewsAvi Kapoor
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains 2%; ABM Industries Shares Plunge After Q2 Results
- NewsAvi Kapoor
Dow Jumps Over 500 Points; Nonfarm Payrolls Top Estimates
- NewsAvi Kapoor
Lululemon Cuts Earnings Forecast, Joins DocuSign, Samsara And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- NewsAvi Kapoor
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
- NewsVandana Singh
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
- NewsAvi Kapoor
Top 3 Health Care Stocks That Could Blast Off This Quarter
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
- Press releaseGlobe Newswire
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
- Press releaseGlobe Newswire
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
- Press releaseGlobe Newswire
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.